Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial
Hauptverfasser: | Rocca, B, Buck, G, Petrucci, G, Parish, S, Pagliaccia, F, Baigent, C, Mafham, M, Bowman, L, Armitage, J, Patrono, C |
---|---|
Weitere Verfasser: | The ASCEND Study Collaborative Group |
Format: | Conference item |
Sprache: | English |
Veröffentlicht: |
Oxford University Press
2020
|
Ähnliche Einträge
-
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
von: Petrucci, G, et al.
Veröffentlicht: (2024) -
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
von: Parish, S, et al.
Veröffentlicht: (2023) -
Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
von: Aung, T, et al.
Veröffentlicht: (2017) -
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
von: Sarah Parish, et al.
Veröffentlicht: (2023-03-01) -
Measurement of Thromboxane Biosynthesis in Health and Disease
von: Carlo Patrono, et al.
Veröffentlicht: (2019-10-01)